THC-CBD Therapy Slashes Chronic Jaw Pain by 90%, Study Finds

For broader context on CBD vs THC as therapeutic agents, see our comparison guide.

A Pain Problem Without Good Solutions

Temporomandibular disorder (TMD) affects an estimated 10 million Americans, causing chronic pain in the jaw joint and surrounding muscles that can make eating, speaking, and even sleeping a daily struggle. For many patients, conventional treatments — NSAIDs, muscle relaxants, physical therapy, occlusal splints — provide only partial relief. Some resort to opioids, with all the associated risks of dependence and side effects.

A study published in the journal Clinics in February 2026 offers a striking alternative: a combination of THC and CBD that reduced functional jaw pain by approximately 90 percent in patients with chronic myofascial TMD.

How the Study Worked

Researchers from Brazilian universities designed a blinded, crossover study involving 20 adults diagnosed with chronic myofascial pain under the Diagnostic Criteria for Temporomandibular Disorders (DC/TMD). This is a well-defined patient population — not vague "jaw pain," but clinically verified chronic myofascial dysfunction.

The study used a crossover design, meaning each participant served as their own control. Participants underwent two consecutive 90-day phases: first a placebo phase, then a Δ9-THC/CBD treatment phase. The cannabinoid therapy used a 1:1 THC-to-CBD ratio, administered sublingually (under the tongue). Dosing started conservatively at 2 milligrams per day in the first week and increased by 2 milligrams per week until reaching 10 milligrams per day by the fifth week, where it remained for the duration of the treatment phase.

This slow titration approach mirrors clinical best practices for cannabinoid therapy: start low, go slow, and let the body adjust.

The Results Were Dramatic

The numbers from this study stand out even in a field where cannabis pain research has shown generally positive trends.

Functional pain — the pain experienced during normal jaw activities like chewing and speaking — dropped by approximately 90 percent during the THC-CBD treatment phase. Allodynia (pain from stimuli that should not normally be painful) and hyperalgesia (heightened sensitivity to painful stimuli) were nearly eliminated.

Objective measurements confirmed the subjective improvements. Maximum mouth opening increased from 45.9 millimeters to 49.9 millimeters — a meaningful gain for patients whose jaw mobility had been compromised by chronic muscle tension and pain. Visual analog scale (VAS) pain scores decreased from 7.35 to 3.50, representing a shift from severe to moderate pain.

Critically, the placebo phase produced minimal improvement, reinforcing that the observed benefits were attributable to the cannabinoid treatment rather than the passage of time, the attention of researchers, or placebo effects. For the underlying cannabis research landscape in 2026, see our overview.

Why This Matters for TMD Patients

TMD is a condition that sits at the intersection of several medical disciplines — dentistry, neurology, pain medicine, rheumatology — and often falls through the cracks of each. Patients frequently cycle through multiple providers, trying various treatments with limited success. The chronic nature of the condition takes a psychological toll, with TMD patients showing elevated rates of anxiety, depression, and sleep disturbance.

A treatment that reduces functional pain by 90 percent — even in a small study — represents a potentially transformative option for this underserved population. The sublingual delivery method is practical and non-invasive, avoiding the respiratory concerns associated with smoking or vaping and the delayed, variable onset of edibles.

The 1:1 THC-to-CBD ratio is also noteworthy. This balanced formulation leverages both cannabinoids' analgesic properties while potentially allowing CBD to modulate some of THC's psychoactive effects, making the treatment more tolerable for daily use.

The Science Behind Cannabis and Jaw Pain

TMD-related myofascial pain involves complex interactions between the nervous system, the immune system, and the musculoskeletal system. Chronic inflammation in the jaw muscles, sensitization of peripheral nerves, and central nervous system changes all contribute to the persistent pain state.

Cannabinoids target several of these mechanisms simultaneously. THC binds to CB1 receptors in the brain and peripheral nerves, directly modulating pain signaling. CBD has anti-inflammatory properties and influences pain processing through multiple pathways, including the TRPV1 receptor and the serotonergic system. Together, they may address both the inflammatory and neurological components of TMD pain in a way that single-mechanism drugs cannot.

The near-elimination of allodynia and hyperalgesia is particularly significant from a neuroscience perspective. These phenomena reflect central sensitization — changes in the spinal cord and brain that amplify pain signals. The fact that THC-CBD therapy reversed these changes suggests it may be addressing the underlying neural dysfunction, not just masking symptoms.

Limitations and Next Steps

The study's main limitation is its small sample size. Twenty participants is enough to generate a compelling signal, but not enough to establish definitive evidence. The crossover design helps mitigate the small sample issue — each participant acting as their own control reduces variability — but larger randomized controlled trials are needed to confirm these findings.

The authors acknowledge this directly, recommending larger studies to validate the results and explore the underlying mechanisms in more detail. Questions remain about optimal dosing, long-term safety, whether the benefits persist after treatment cessation, and whether certain TMD subtypes respond better than others.

A New Chapter for Cannabis Pain Research

This study arrives at a fortuitous time for cannabis pain research. With marijuana's reclassification to Schedule III removing significant barriers to federal research, and over 70 cannabis studies already published in 2026, the conditions for rigorous clinical investigation have never been better.

For the millions of Americans living with chronic TMD pain, the Brazilian study offers something rare: a dramatically positive result from a well-designed clinical trial, using a practical delivery method at manageable doses. Whether this signal translates into standard-of-care treatment will depend on the larger studies to come. But for a patient population that has long been underserved by conventional medicine, even the possibility of 90 percent pain reduction is worth pursuing.